Abstractα-Synucleinopathies are neurodegenerative disorders that range pathologically from the demise of select groups of nuclei to pervasive degeneration throughout the neuraxis. Although mounting evidence suggests that α-synuclein lesions lead to neurodegeneration, this remains controversial. To explore this issue, we generated transgenic mice expressing wild-type and A53T human α-synuclein in CNS neurons. Mice expressing mutant, but not wild-type, α-synuclein developed a severe and complex motor impairment leading to paralysis and death. These animals developed age-dependent intracytoplasmic neuronal α-synuclein inclusions paralleling disease onset, and the α-synuclein inclusions recapitulated features of human counterparts. Moreover, im...
Alpha-synucleinopathies are a group of progressive neurodegenerative disorders, characterized by int...
Abstract \u3b1-Synuclein is a protein implicated in the etiopathogenesis of Parkinson...
α-Synuclein is a protein implicated in the etiopathogenesis of Parkinson’s disease (PD). AAV1/2-driv...
alpha-Synucleinopathies are neurodegenerative disorders that range pathologically from the demise of...
Abstractα-Synucleinopathies are neurodegenerative disorders that range pathologically from the demis...
Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuc...
α-Synuclein (αSN) in human is tightly linked both neuropathologically and genetically to Parkinson's...
Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuc...
<p>Human specific α-syn was expressed in neurons and neuropil of A53T homozygote (top panel), but no...
Abstract Background Progressive accumulation of α-synuclein (α-Syn) protein in different brain regio...
Alpha-synucleinopathies are a group of progressive neurodegenerative disorders, characterized by int...
Abstract Degeneration of noradrenergic locus coeruleus neurons occurs during the prodromal phase of ...
Abstract: Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A5...
In Parkinson’s disease and dementia with Lewy bodies, α-synuclein aggregates to form oligomers and f...
SummaryTransgenic (Tg) mice overexpressing human wild-type α-synuclein in oligodendrocytes under the...
Alpha-synucleinopathies are a group of progressive neurodegenerative disorders, characterized by int...
Abstract \u3b1-Synuclein is a protein implicated in the etiopathogenesis of Parkinson...
α-Synuclein is a protein implicated in the etiopathogenesis of Parkinson’s disease (PD). AAV1/2-driv...
alpha-Synucleinopathies are neurodegenerative disorders that range pathologically from the demise of...
Abstractα-Synucleinopathies are neurodegenerative disorders that range pathologically from the demis...
Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuc...
α-Synuclein (αSN) in human is tightly linked both neuropathologically and genetically to Parkinson's...
Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuc...
<p>Human specific α-syn was expressed in neurons and neuropil of A53T homozygote (top panel), but no...
Abstract Background Progressive accumulation of α-synuclein (α-Syn) protein in different brain regio...
Alpha-synucleinopathies are a group of progressive neurodegenerative disorders, characterized by int...
Abstract Degeneration of noradrenergic locus coeruleus neurons occurs during the prodromal phase of ...
Abstract: Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A5...
In Parkinson’s disease and dementia with Lewy bodies, α-synuclein aggregates to form oligomers and f...
SummaryTransgenic (Tg) mice overexpressing human wild-type α-synuclein in oligodendrocytes under the...
Alpha-synucleinopathies are a group of progressive neurodegenerative disorders, characterized by int...
Abstract \u3b1-Synuclein is a protein implicated in the etiopathogenesis of Parkinson...
α-Synuclein is a protein implicated in the etiopathogenesis of Parkinson’s disease (PD). AAV1/2-driv...